Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
testosterone enanthate + carboplatin
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
This is a combination therapy consisting of testosterone enanthate, an esterified form of the androgen hormone testosterone, and carboplatin, a platinum-based chemotherapeutic agent. Testosterone enanthate acts as an agonist at the androgen receptor to replace or supplement endogenous testosterone levels. Carboplatin is an alkylating agent that forms DNA crosslinks leading to apoptosis in rapidly dividing cells. This combination has been studied in clinical trials for metastatic castrate-resistant prostate cancer (mCRPC), particularly in patients without homologous recombination deficiency (HRD). The rationale for this combination includes exploiting the potential synergy between hormonal manipulation (bipolar androgen therapy) and DNA-damaging chemotherapy[1][3].
- Other names
- testosterone enanthate and carboplatinhigh dose testosterone + carboplatin
02
Targets
AR (Adrenergic receptors)DNA
Beyond the preview
Go deeper on testosterone enanthate + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on testosterone enanthate + carboplatin.